The use of TLR4 agonist has shown to lead to higher secretion of pro-inflammatory mediators (such as IL-6, IL-17, and IL-1b) and to impede secretion of anti-inflammatory IL-10 in PBMCs of NMO patients [69,70]. Here, IL6 is linked to neuromyelitis optica.